338 related articles for article (PubMed ID: 38205881)
1. PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer.
Rutherford KA; McManus KJ
Mol Cancer Ther; 2024 Apr; 23(4):454-463. PubMed ID: 38205881
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
3. Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC).
Dogheim GM; Amralla MT
Drug Dev Res; 2023 Jun; 84(4):629-653. PubMed ID: 37020351
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
6. [Application of PROTACs in Hematological Malignancies--Review].
Jia YN; Mi YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1921-1924. PubMed ID: 38071084
[TBL] [Abstract][Full Text] [Related]
7. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
Sincere NI; Anand K; Ashique S; Yang J; You C
Molecules; 2023 May; 28(10):. PubMed ID: 37241755
[TBL] [Abstract][Full Text] [Related]
8. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
[TBL] [Abstract][Full Text] [Related]
10. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
Yao R; Luo T; Wang M
Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
[TBL] [Abstract][Full Text] [Related]
11. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
12. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
Yang W; Saboo S; Zhou L; Askin S; Bak A
Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
[TBL] [Abstract][Full Text] [Related]
13. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
Xie H; Zhang C
Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
[TBL] [Abstract][Full Text] [Related]
14. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
15. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
Wu Y; Zhang J; Zhu X; Zhang Y
Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
[TBL] [Abstract][Full Text] [Related]
16. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
Nalawansha DA; Crews CM
Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
[TBL] [Abstract][Full Text] [Related]
17. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
18. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
Wang C; Zhang Y; Chen W; Wu Y; Xing D
Mol Cancer; 2024 May; 23(1):110. PubMed ID: 38773495
[TBL] [Abstract][Full Text] [Related]
19. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
[TBL] [Abstract][Full Text] [Related]
20. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety.
Zhang R; Xie S; Ran J; Li T
J Cell Physiol; 2024 May; 239(5):e31255. PubMed ID: 38501341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
